Premium
P1‐044: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of LY3202626, a Novel Bace1 Inhibitor, in Healthy Subjects and Patients with Alzheimer’s Disease
Author(s) -
Willis Brian A.,
Lowe Stephen L.,
Daugherty Leslie L.,
Dean Robert A.,
English Brett,
Ereshefsky Larry,
Gevorkyan Hakop,
James Douglas E.,
Jhee Stanford,
Lin Qun,
Lo Albert,
Mergott Dustin J.,
Monk Scott A.,
Nakano Masako,
Zimmer Jennifer A.,
Irizarry Michael C.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.791
Subject(s) - tolerability , pharmacokinetics , pharmacodynamics , medicine , placebo , cmax , pharmacology , adverse effect , anesthesia , pathology , alternative medicine